标题
Development of SGLT1 and SGLT2 inhibitors
作者
关键词
Chronic kidney disease, Drug development, Heart failure, Inhibitor, Intestinal glucose transport, Renal glucose transport, Review, Sodium–glucose cotransporter, Type 1 diabetes, Type 2 diabetes
出版物
DIABETOLOGIA
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-07-21
DOI
10.1007/s00125-018-4654-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus
- (2018) Hadi Fattah et al. DRUGS
- Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation
- (2017) Toshihiro Inoue et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A dual agonist of farnesoid X receptor (FXR) and the G protein–coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice
- (2017) Xiaoxin X. Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes
- (2017) Nicole C. Goodwin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
- (2017) Satish K. Garg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
- (2017) Paresh Dandona et al. Lancet Diabetes & Endocrinology
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
- (2017) Christoph Wanner et al. CIRCULATION
- Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
- (2016) Volker Vallon et al. DIABETOLOGIA
- Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus
- (2016) Panai Song et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants
- (2016) LANCET
- Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents
- (2016) Chang-Ik Choi MOLECULES
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release
- (2015) Robert L. Dobbins et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy
- (2015) Marko Škrtić et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
- (2015) Silvio E Inzucchi et al. Diabetes & Vascular Disease Research
- Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor
- (2015) Pablo Lapuerta et al. Diabetes & Vascular Disease Research
- Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences
- (2015) Linda A Gallo et al. Diabetes & Vascular Disease Research
- Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
- (2015) Arthur T. Sands et al. DIABETES CARE
- Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
- (2015) Robert R. Henry et al. DIABETES CARE
- Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)
- (2015) T. R. Pieber et al. DIABETES OBESITY & METABOLISM
- Regulation of intestinal SGLT1 by catestatin in hyperleptinemic type 2 diabetic mice
- (2015) Jessica A Dominguez Rieg et al. LABORATORY INVESTIGATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study
- (2014) Kamlesh Khunti et al. DIABETES CARE
- KATP channel as well as SGLT1 participates in GIP secretion in the diabetic state
- (2014) Hidetada Ogata et al. JOURNAL OF ENDOCRINOLOGY
- The Role of SGLT1 and GLUT2 in Intestinal Glucose Transport and Sensing
- (2014) Pia V. Röder et al. PLoS One
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
- (2013) T. Heise et al. DIABETES OBESITY & METABOLISM
- Improved glycemic control in mice lacking Sglt1 and Sglt2
- (2012) David R. Powell et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial
- (2012) B Zambrowicz et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Na+-D-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion
- (2011) V. Gorboulev et al. DIABETES
- Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
- (2011) S. Sha et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
- An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
- (2011) Frank A. Holtkamp et al. KIDNEY INTERNATIONAL
- SGLT2 inhibitors: molecular design and potential differences in effect
- (2011) Masayuki Isaji KIDNEY INTERNATIONAL
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- A Study of Orthoglycaemic Glycosuria with Particular Reference to its Hereditability.
- (2010) URBAN HJÄRNE. ACTA MEDICA SCANDINAVICA
- Cardiovascular Disease in Type 2 Diabetes From Population to Man to Mechanisms: The Kelly West Award Lecture 2008
- (2010) M. Laakso DIABETES CARE
- SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
- (2010) V. Vallon et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice
- (2009) Ryuichi Moriya et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target
- (2009) R. Santer et al. Clinical Journal of the American Society of Nephrology
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The effects of glucagon-like peptide-1 on the beta cell
- (2009) T. Vilsbøll DIABETES OBESITY & METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started